Dahiliye Polikliniğine Başvuran Tip 2 Diyabetli Hastalarda Covid-19 Pandemi Sürecinin Hba1c Üzerine Etkisi

Yıl 2026, Cilt: 48 Sayı: 2, 199 - 209, 11.02.2026

Fatih Orhan , Mustafa Asım Gedikli , Zekeriya Keskin

https://doi.org/10.20515/otd.1628201

Öz

Tip 2 Diyabetes Mellitus'un (DM) insidansı ve yaygınlığı dünya çapında artmaktadır. Pandemi sırasında kısıtlamalar, artan stres ve artan hareketsiz yaşam nedeniyle diyabet kontrolünde bozulma beklenmektedir. Bu çalışmanın amacı COVID-19’un HbA1c değerleri üzerine etkisini ve diyabet kontrolünü nasıl etkilediğini belirlemektir. Çalışmamızda 5 ayrı dönemde (Mart 2018-Şubat 2019, Mart 2019-Şubat 2020, Mart 2020-Şubat 2021, Mart 2021-Şubat 2022, Mart 2022-Şubat 2023) toplam 6217 diyabetik hasta retrospektif olarak incelendi. HbA1c değerine göre; HbA1c değeri %7’nin altında olanlar iyi kontrol, %7-9 arasında olanlar kötü kontrol, %9'dan fazla olanlar ise çok kötü kontrol altında olarak sınıflandırıldı. Ayrıca LDL, HDL, kolesterol ve açlık kan şekeri değerleri kaydedildi. Gruplar arasında HbA1c ölçümleri açısından anlamlı fark bulundu (p<0.001). En düşük HbA1c değeri Mart 2018-Şubat 2019 tarihleri arasındaki ölçümde %7,61 olarak bulunurken, en yüksek değer Mart 2020-Şubat 2021 tarihleri arasındaki ölçümde %8,39 olarak bulundu. HbA1c çok zayıf kontrol oranı Mart 2020 ve Şubat 2021'de (%30,9) en yüksek, iyi kontrol oranı ise Mart 2018 ve Şubat 2019'da (%51,3) en yüksek idi. Çalışmamızda pandemi döneminde HbA1c değerleri ve kötü kontrol edilen hasta oranlarının daha yüksek olduğu bulunmuştur. Bu sonuç göz önüne alındığında pandemi sürecinin Tip 2 diyabetli hastalarda hastalık kontrolünde bozulmaya neden olduğu söylenebilir.

Anahtar Kelimeler

Diyabetes Mellitus , HbA1c , COVİD-19 , Pandemi

Etik Beyan

Çalışmaya başlamadan önce Sivas Cumhuriyet Üniversitesi Girişimsel Olmayan Etik Kurulu’ndan 17.05.2023 tarih ve 2023/05-39 sayılı etik kurul onayı alındı.

The Effect of the Covid-19 Pandemic Process on Hba1c In Type 2 Diabetes Patients Applying to the Internal Medicine Outpatient Clinic

Öz

The incidence and prevalence of Type 2 Diabetes Mellitus (DM) are increasing worldwide. Due to the restrictions, increased stress, and increased sedentary life during the pandemic, deterioration in diabetes control is expected. The aim of this study is to determine the effect of COVID-19 on HbA1c values and how it affects diabetes control. In our study, a total of 6217 diabetic patients were examined retrospectively in 5 separate periods (March 2018-February 2019, March 2019-February 2020, March 2020-February 2021, March 2021-February 2022, March 2022-February 2023). According to the HbA1c value; those with HbA1c values were classified as well-controlled, those between 7-9% as poorly controlled, and those >9% as very poorly controlled. In addition, LDL, HDL, cholesterol and fasting blood sugar values were recorded. There are significant differences between the groups in terms of HbA1c measurements (p<0.001). The lowest HbA1c value was found to be 7.61% in the measurement between March 2018 and February 2019, and the highest value was found to be 8.39% in the measurement between March 2020 and February 2021. The HbA1c very poor control rate was the highest in March 2020 and February 2021 (30.9%), and the good control rate was the highest in March 2018 and February 2019 (51.3%). In our study, HbA1c values and poorly controlled patient rates were found to be higher during the pandemic period. Considering this result, it can be said that the pandemic process caused deterioration in disease control in Type 2 diabetes patients.

Anahtar Kelimeler

Diabetes Mellitus , HbA1c , COVİD-19 , Pandemic

Etik Beyan

Before the study, ethics committee approval was obtained from Sivas Cumhuriyet University Non-Interventional Ethics Committee dated 17.05.2023 and numbered 2023/05-39.

Kaynakça

• 1. Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 2020;16(7):377-390.
• 2. Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing Type 2 Diabetes: A Narrative Review of the Evidence. Nutrients 2019;11(4):766.
• 3. Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, Pfeiffer A, Thanopoulou A, Salas-Salvadó J, Schwab U, Sievenpiper JL. Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. Nutrients 2019;11(11):2611.
• 4. Felix HC, Andersen JA, Willis DE, Malhis JR, Selig JP, McElfish PA. Control of type 2 diabetes mellitus during the COVID-19 pandemic. Prim Care Diabetes 2021;15(5):786-792.
• 5. Kone N, Cassim N, Maposa I, George JA. Diabetic control and compliance using glycated haemoglobin (HbA1C) testing guidelines in public healthcare facilities of Gauteng province, South Africa. PLoS One 2023;18(8):e0278789.
• 6. Yan Y, Wu T, Zhang M, Li C, Liu Q, Li F. Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population. BMC Public Health 2022;22(1):1382.
• 7. Zhang XX, Kong J, Yun K. Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies. J Diabetes Res 2020;2020:2315607.
• 8. Shibata S, Kobayashi K, Tanaka M, Asayama K, Yamamoto E, Nakagami H, Hoshide S, Kishi T, Matsumoto C, Mogi M, Morimoto S, Yamamoto K, Mukoyama M, Kario K, Node K, Rakugi H. COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. Hypertens Res 2023;46(3):589-600.
• 9. Laffin LJ, Kaufman HW, Chen Z, Niles JK, Arellano AR, Bare LA, Hazen SL. Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic. Circulation 2022;145(3):235-237.
• 10. Papaioannu Borjesson R, Galli L, Muccini C, Poli A, Clemente T, Bottanelli M, Gianotti N, Nozza S, Castagna A, Spagnuolo V. Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic. Front Med (Lausanne) 2023;10:1220631.
• 11. Karatas S, Yesim T, Beysel S. Impact of lockdown COVID-19 on metabolic control in type 2 diabetes mellitus and healthy people. Prim Care Diabetes 2021;15(3):424-427.
• 12. Biamonte E, Pegoraro F, Carrone F, Facchi I, Favacchio G, Lania AG, Mazziotti G, Mirani M. Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect. Endocrine 2021;72(3):604-610.
• 13. Önmez A, Gamsızkan Z, Özdemir Ş, Kesikbaş E, Gökosmanoğlu F, Torun S, Cinemre H. The effect of COVID-19 lockdown on glycemic control in patients with type 2 diabetes mellitus in Turkey. Diabetes Metab Syndr 2020;14(6):1963-1966.
• 14. Selek A, Gezer E, Altun E, Sözen M, Topaloğlu Ö, Köksalan D, Demirkan H, Karakaya D, Cetinarslan B, Cantürk Z, Taymez D. The impact of COVID-19 pandemic on glycemic control in patients with diabetes mellitus in Turkey: a multi-center study from Kocaeli. J Diabetes Metab Disord 2021;20(2):1461-1467.
• 15. Takebayashi K, Yamauchi M, Hara K, Tsuchiya T, Hashimoto K. Seasonal variations and the influence of COVID-19 pandemic on hemoglobin A1c, glycoalbumin, and low-density lipoprotein cholesterol. Diabetol Int 2022;13(4):599-605.
• 16. Farhane H, Motrane M, Anaibar FE, Motrane A, Abeid SN, Harich N. COVID-19 pandemic: Effects of national lockdown on the state of health of patients with type 2 diabetes mellitus in a Moroccan population. Prim Care Diabetes 2021;15(5):772-777.
• 17. Munekawa C, Hosomi Y, Hashimoto Y, Okamura T, Takahashi F, Kawano R, Nakajima H, Osaka T, Okada H, Majima S, Senmaru T, Nakanishi N, Ushigome E, Hamaguchi M, Yamazaki M, Fukui M. Effect of coronavirus disease 2019 pandemic on the lifestyle and glycemic control in patients with type 2 diabetes: a cross-section and retrospective cohort study. Endocr J 2021;68(2):201-210.
• 18. Jin J, Lee SW, Lee WK, Jeon JH, Kim JG, Lee IK, Choi YK, Park KG. Year-Long Trend in Glycated Hemoglobin Levels in Patients with Type 2 Diabetes during the COVID-19 Pandemic. Endocrinol Metab (Seoul) 2021;36(5):1142-1146.
• 19. D'Onofrio L, Pieralice S, Maddaloni E, Mignogna C, Sterpetti S, Coraggio L, Luordi C, Guarisco G, Leto G, Leonetti F, Manfrini S, Buzzetti R. Effects of the COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study. Diabetes Obes Metab 2021;23(7):1624-1630.
• 20. Alowainati B, Dabbous Z, Salameh O, Hamad M, Al Hail L, Abuheliqa W, Al Janahi I, Jayyousi A, Zirie M. The impact of lockdown and changes in clinical practice on glycemic control during the COVID-19 pandemic: analysis of data from the National Diabetes Center, Doha, Qatar, J. Diabetes Endocr. Pract 2021;4(4):197–201.
• 21. Auriemma RS, Pirchio R, Liccardi A, Scairati R, Del Vecchio G, Pivonello R, Colao A. Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. J Endocrinol Invest 2021;44(12):2845-2847.